Kolon Life Science Inc. (102940.KQ)
KRW 22850.0
(0.22%)
KRW 22850.0
(0.22%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -24.86 Billion | -20.85 Billion | -16.18 Billion | -7.3 Billion | -20.18 Billion |
| Net Income | -30.72 Billion | 2.13 Billion | -1.37 Billion | -43.19 Billion | -92.32 Billion |
| Depreciation & Amortization | 8.83 Billion | 9.46 Billion | 11.29 Billion | 13.02 Billion | 14.03 Billion |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - |
| Change in working capital | -10.5 Billion | -34.51 Billion | -32.12 Billion | 8.24 Billion | -12.4 Billion |
| Other non-cash items | 8.88 Billion | 1.77 Billion | 7.88 Billion | 5.37 Billion | 70.5 Billion |
| Investing Cash Flow | -7.02 Billion | -5.93 Billion | -2.25 Billion | 19.03 Billion | -19.61 Billion |
| Investments in PPE | -10.23 Billion | -6.3 Billion | -4.45 Billion | -2.74 Billion | -30.77 Billion |
| Acquisitions | - | - | - | - | - |
| Investment purchases | -120 Million | - | -110 Million | -14.23 Billion | -1.55 Billion |
| Sales/Maturities of investments | 105.46 Million | 360 Million | 2.33 Billion | 15 Billion | - |
| Other Investing Activities | -274.47 Million | -9.12 Million | -190.44 Million | 21.01 Billion | 11.16 Billion |
| Financing Cash Flow | 32.88 Billion | 5.45 Billion | 30.94 Billion | -2.37 Billion | 13.01 Billion |
| Debt repayment | -33.75 Billion | -5.51 Billion | -7.97 Billion | -1.79 Billion | -7.99 Billion |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - |
| Other Financing Activities | -20.00 | 653.59 Million | 39.56 Billion | 8.14 Billion | 21 Billion |
| Accounts receivables | 4.71 Billion | -10.66 Billion | 2.5 Billion | 6.26 Billion | -5.98 Billion |
| Accounts payables | - | - | - | - | - |
| Inventory | -2.12 Billion | -23.84 Billion | -3.8 Billion | -3.55 Billion | -2.72 Billion |
| Other working capital | -7.64 Billion | -3.12 Billion | -32.77 Billion | 4.36 Billion | -3.69 Billion |
| Cash at beginning of period | 6.37 Billion | 27.8 Billion | 15 Billion | 5.91 Billion | 32.67 Billion |
| Cash at end of period | 7.56 Billion | 6.37 Billion | 27.8 Billion | 15 Billion | 5.91 Billion |
| Capital Expenditure | -10.23 Billion | -6.3 Billion | -4.45 Billion | -2.74 Billion | -30.77 Billion |
| Effect of forex changes on cash | 192.24 Million | -96.33 Million | 292.45 Million | -264.02 Million | 22.28 Million |
| Net cash flow / Change in cash | 1.19 Billion | -21.42 Billion | 12.79 Billion | 9.08 Billion | -26.75 Billion |
| Free Cash Flow | -35.1 Billion | -27.16 Billion | -20.64 Billion | -10.05 Billion | -50.95 Billion |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -59.31 Billion | -4.54 Billion | -13.41 Billion | -30.72 Billion | -7.01 Billion | -5.63 Billion |
| Depreciation & Amortization | 2.07 Billion | 2.08 Billion | 2.14 Billion | 8.83 Billion | 2.13 Billion | 2.28 Billion |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 2.17 Billion | -7.92 Billion | -7.24 Billion | -10.5 Billion | -724.92 Million | -1.31 Billion |
| Other non-cash items | 52.53 Billion | 1.87 Billion | 4.57 Billion | 8.88 Billion | 1.66 Billion | 1.42 Billion |
| Investing Cash Flow | -1.84 Billion | -2.6 Billion | -1.91 Billion | -7.02 Billion | -3.97 Billion | -2.71 Billion |
| Investments in PPE | -1.5 Billion | -2.6 Billion | -1.91 Billion | -10.23 Billion | -3.93 Billion | -3.17 Billion |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | -120 Million | - | - |
| Sales/Maturities of investments | - | - | - | 105.46 Million | - | - |
| Other Investing Activities | -342.44 Million | -23 Million | -3 Million | -274.47 Million | -44 Million | -24.47 Million |
| Financing Cash Flow | 21.46 Billion | 15.12 Billion | 9.53 Billion | 32.88 Billion | -6.72 Billion | 24.9 Billion |
| Debt repayment | -186.54 Million | -15.35 Billion | -9.76 Billion | -33.75 Billion | -6.49 Billion | -25.13 Billion |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | 21.64 Billion | -10.00 | 9.53 Billion | -20.00 | -6.72 Billion | 24.9 Billion |
| Accounts receivables | -1.99 Billion | -6.7 Billion | - | 4.71 Billion | 1.89 Billion | 3.13 Billion |
| Accounts payables | - | - | - | - | - | - |
| Inventory | 3.77 Billion | 241.88 Million | 525.55 Million | -2.12 Billion | -4.63 Billion | 2.85 Billion |
| Other working capital | 386.72 Million | -2.85 Billion | -5.63 Billion | -7.64 Billion | 1.98 Billion | -1.96 Billion |
| Cash at beginning of period | 8.38 Billion | 7.56 Billion | 11.41 Billion | 6.37 Billion | 26.04 Billion | 6.83 Billion |
| Cash at end of period | 25.56 Billion | 8.38 Billion | 7.56 Billion | 7.56 Billion | 11.41 Billion | 26.04 Billion |
| Capital Expenditure | -1.5 Billion | -2.6 Billion | -1.91 Billion | -10.23 Billion | -3.93 Billion | -3.17 Billion |
| Effect of forex changes on cash | 92.64 Million | 102.15 Million | 8.64 Million | 192.24 Million | 47.56 Million | 76.33 Million |
| Net cash flow / Change in cash | 17.17 Billion | 825.36 Million | -3.85 Billion | 1.19 Billion | -14.63 Billion | 19.21 Billion |
| Free Cash Flow | -4.03 Billion | -14.38 Billion | -13.39 Billion | -35.1 Billion | -7.9 Billion | -6.23 Billion |
IART
CPAC
4378
TLIS
9969
0623